Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Everest MedicinesSTU:6HN -0.71%51 Days Payable is 60.50 as of Dec. 2025, which is 98% below its 10-year median of 2,563.64. GuruFocus rates STU:6HN with a GF Score™ of 51/100 and a GF Value™ of €32.66 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 702 Biotechnology companies, Everest Medicines ranks worse than 59.26% on this metric.
The historical rank and industry rank for Everest Medicines's Days Payable or its related term are showing as below:
STU:6HN'
s Days Payable Range Over the Past 10 Years
Min: 68.57 Med: 2563.64 Max: 751033.13
Current: 68.57
During the past 8 years, Everest Medicines's highest Days Payable was 751033.13. The lowest was 68.57. And the median was 2563.64.
STU:6HN's Days Payable is ranked worse than 59.26% of 702
companies
in the Biotechnology industry
Industry Median: 113.1
vs STU:6HN: 68.57
Everest Medicines's Days Payable
declined
from Dec. 2024 (95.73) to Dec. 2025 (60.50).
It may suggest that Everest Medicinesaccelerated paying its suppliers.
Everest Medicines Days Payable Related Terms
Everest Medicines Days Payable Historical Data
* Premium members only.
The historical data trend for Everest Medicines's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:6HN vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, Everest Medicines's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Everest Medicines Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Everest Medicines's Days Payable distribution charts can be found below:
* The bar in red indicates where Everest Medicines's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Everest Medicines's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Everest Medicines (STU:6HN) has a Days Payable of 60.50 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Everest Medicines and its competitors. This is 98% below median its historical median of 2,563.64. Over the past decade, Everest Medicines' Days Payable has ranged from 68.57 to 751,033.13. According to the industry distribution chart, Everest Medicines ranks #416 out of 702 companies in the Biotechnology industry, placing it in the top 59.3%.
Is Everest Medicines' Days Payable too high?
Everest Medicines' current Days Payable of 60.50 is 98% below median its 10-year median of 2,563.64. Over the past 10 years, this metric has ranged from a low of 68.57 to a high of 751,033.13. The Biotechnology industry median Days Payable is 113.10. Everest Medicines' value of 60.50 is 46.5% below this industry median. Based on the distribution chart, Everest Medicines ranks #416 out of 702 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Everest Medicines has a GF Score™ of 51/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Everest Medicines' Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Everest Medicines ranks #416 out of 702 companies for Days Payable. This places Everest Medicines in the lower half of its industry. The industry median Days Payable is 113.10. Everest Medicines' value of 60.50 is 46.5% below this benchmark. Historically, Everest Medicines' own Days Payable has ranged from 68.57 to 751,033.13 over the past decade. While the company's 10-year median is 2,563.64 vs. the industry median of 113.10, Everest Medicines has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.10, based on 702 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Everest Medicines's current Days Payable of 60.50 is 46.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Everest Medicines and its competitors. For the Biotechnology industry, the median Days Payable is 113.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Everest Medicines's current Days Payable is 60.50, which is 98% below median its own 10-year median of 2,563.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Everest Medicines stock overvalued right now?
Based on GuruFocus' analysis, Everest Medicines (STU:6HN) is currently considered Possible Value Trap. The stock's GF Value™ is €32.66, compared to a current price of €2.80 — trading 91.4% below its estimated fair value. The current Days Payable is 60.50, which is 98% below median its 10-year median of 2,563.64 and 46.5% below the Biotechnology industry median of 113.10. Everest Medicines' overall GF Score™ is 51/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Everest Medicines (STU:6HN), the current Days Payable is 60.50 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Everest Medicines (STU:6HN) Overvalued in 2026?
Based on GuruFocus' analysis, Everest Medicines stock appears to be undervalued.
The current stock price of €2.80 is trading 91.4% below its estimated GF Value™ of €32.66.
GuruFocus considers Everest Medicines to be Possible Value Trap.
Key valuation signals for STU:6HN:
Days Payable: 60.50 (98% below median its 10-year median of 2,563.64)
GF Value™: €32.66 vs. price of €2.80 (91.4% below fair value)
Industry Position: 46.5% below the Biotechnology median (#416 of 702)
No single metric tells the full story. See the STU:6HN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Everest Medicines Ltd is a biopharmaceutical company that integrates discovery, licensing, clinical development, commercialization, and manufacturing of potentially novel or differentiated therapies and vaccines to address critical unmet medical needs initially in the Asia Pacific markets and eventually around the world. Its product pipeline includes: Nefecon (TarpeyoTM), EVER001, Eravacycline (Xerava), SPR206, and others. Geographically operates in Mainland China.
51GF Score
Get the complete analysis for STU:6HN
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:6HN has been successfully added to your 
